# A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

> **NCT06778863** · PHASE1 · RECRUITING · sponsor: **Clasp Therapeutics, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Unresectable Solid Tumor
- Metastatic Solid Tumor
- Colorectal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Lung Cancer
- Ovarian Cancer
- Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Prostate Cancer
- Bladder Cancer

## Interventions

- **DRUG:** CLSP-1025

## Key facts

- **NCT ID:** NCT06778863
- **Lead sponsor:** Clasp Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06778863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06778863, "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06778863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*